WHO Solidarity Trial: Repurposed Antiviral Drugs for Covid-19
| Name of the Trial |
| WHO Solidarity Trial |
| Title of the Trial |
| Repurposed Antiviral Drugs for Covid-19 |
| Design |
| Open-label, randomized controlled trial |
| Year of Publication |
| 2020 |
| Objective |
| To assess the safety and efficacy of four drugs: remdesivir, hydroxychloroquine, lopinavir, interferon in treating patients hospitalized with coronavirus disease 2019 (COVID-19) |
| Number of Patients (N) |
| 11266 |
| Inclusion Criteria |
| -Age ≥18 years -Hospitalization with COVID-19 -Not known to have received any trial drug -Were not expected to be transferred elsewhere within 72 hours -No contraindications |
| Exclusion criteria |
| -hypersensitivity to tocilizumab -Pregnancy -Active bacterial infection -Severely Neutropenic, thrombocytopenic |
| Duration of Follow up |
| 28 days |
| Comparison groups |
| Remdesivir (n = 2,750), Hydroxychloroquine (n = 954), lopinavir without interferon (n = 1,411), interferon with or without lopinavir (n = 2,063), no trial drug (n = 4,088) |
| Primary Outcomes |
| In-hospital mortality Remdesivir vs. control: 12.5% vs. 12.7%, p = 0.5 Hydroxychloroquine vs. control: 10.2% vs. 8.9%, p = 0.23 Lopinavir vs. control: 9.7% vs. 10.3%, p = 0.97 Interferon vs. control: 12.9% vs. 11%, p = 0.11 |
| Key Secondary Outcomes |
| No drug definitely reduced mortality, overall or in any subgroup, or reduced initiation of ventilation or hospitalization duration. |
| Conclusion |
| Remdesivir, hydroxychloroquine, lopinavir, and interferon regimens had little or no effect on hospitalized patients with Covid-19, as indicated by overall mortality, initiation of ventilation, and duration of hospital stay. |
| Citation, article link |
| WHO Solidarity Trial Consortium. Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results. NEJM, 2020. |